BioAge Labs, Inc. 8K

BioAge Labs reported Q2 2026 results, advanced its lead NLRP3 inhibitor BGE-102 into Phase 2 (QUELL-CV) with a planned ocular trial (QUELL-DME), and reaffirmed a strong cash runway through 2029 despite a higher quarterly net loss.

BioAge Labs, Inc. reported its second quarter 2026 financial results and provided business updates, highlighting the June 2026 dosing of the first participant in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of its oral NLRP3 inhibitor BGE-102 in obese patients with elevated inflammation, and plans to initiate QUELL-DME, a Phase 1b/2a trial of BGE-102 in diabetic macular edema, in mid-2026 with data expected in mid-2027. The company discussed Phase 1 data showing BGE-102 achieved up to 98% suppression of IL-1β and substantial hsCRP reductions with a favorable safety profile, and noted continued advancement of its APJ agonist obesity program and strategic collaborations with Novartis and Lilly ExploRD. Financially, BioAge recorded $2.45 million in collaboration revenue, a net loss of $26.1 million for the quarter, increased R&D spending primarily driven by BGE-102 program costs, and ended June 30, 2026 with $381.3 million in cash, cash equivalents, and marketable securities, which management believes will fund operations through 2029.

Filing Facts

CIK

1709941

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-335368

Alert Tier

6